IRVINE, Calif. and LONDON--(BUSINESS WIRE)--Somanta Pharmaceuticals (OTCBB:SMPM) today announced that data from its Alchemix program will be presented later today at the American Association for Cancer Research Annual Meeting in Los Angeles. The poster presentation is entitled “Cytotoxicity of novel alkylating anthraquinones in cells with DNA Nucleotide Excision Repair and DNA Mismatch Repair defects,” and focuses on structure-activity studies on the company’s novel technology for targeting and irreversibly binding to DNA / DNA processing enzymes. The studies reported in the poster were conducted at the Institute for Cancer Therapeutics at the University of Bradford, Bradford, United Kingdom (www.cancer.Brad.ac.uk) under the collaborative research agreement announced previously.
